Bio-Works Technologies Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Lone Carlbom

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth

Dec 25

Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth

Aug 30

We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth

Feb 21

We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth

Oct 25

We Think Bio-Works Technologies (STO:BIOWKS) Can Easily Afford To Drive Business Growth

May 10

Bio-Works Technologies (STO:BIOWKS) Is In A Strong Position To Grow Its Business

Sep 27

Is Bio-Works Technologies (STO:BIOWKS) In A Good Position To Invest In Growth?

May 11

Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Have Been Selling

Mar 20

How Much Are Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Taking Off The Table?

Dec 05

CEO

Lone Carlbom

less than a year

Tenure

Ms. Lone Carlbom is Chief Executive Officer of Bio-Works Technologies AB (publ) from May 17, 2024. Ms. Carlbom has broad experience in leadership roles within the Life Sciences and Biotech industries, with...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lone Carlbom	Chief Executive Officer	less than a year	geen gegevens	geen gegevens
Jan Berglöf	Co-Founder & Senior Advisor	4yrs	geen gegevens	geen gegevens
Arne Hauge	CFO & Head of Support Functions	1.3yrs	geen gegevens	geen gegevens
Karsten Fjärstedt	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Helena Pahlm	Senior Director of Global Quality	no data	geen gegevens	geen gegevens
Silvia Hellstrom	Head of Quality Assurance	no data	geen gegevens	geen gegevens
Maria Åberg	Head of Production	no data	geen gegevens	geen gegevens
Anne Dyrdal	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van BIOWKS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter von Ehrenheim	Independent Chairman of the Board	5.2yrs	SEK 237.00k	1.53% SEK 1.1m
Thomas Gür	Director	less than a year	geen gegevens	geen gegevens
Peter Nahlstedt	Independent Board Director	4.5yrs	SEK 118.00k	geen gegevens
Kirsti Gjellan	Independent Board Director	6.5yrs	SEK 118.00k	geen gegevens
Jurgen Hubbuch	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jean Bender	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Eun Lee	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Per Möller	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jorg Thommes	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jonas Ahlen	Director	less than a year	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOWKS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bio-Works Technologies Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Bio-Works Technologies AB (publ) Approves Appointment of Jonas Ahlen and Thomas Gür as New Board Members

Bio-Works Technologies AB (Publ) Announces Executive Changes

Bio-Works Technologies AB (Publ) Announces Executive Changes

Bio-Works Technologies AB (publ) Announces Johan Sedihn Declines Re-Election as Member of Board

Independent Chairman of the Board recently bought kr510k worth of stock

Independent Chairman of the Board recently bought kr275k worth of stock

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings released: kr0.12 loss per share (vs kr0.38 loss in 3Q 2023)

New major risk - Financial position

Bio-Works Technologies AB (publ) Approves Appointment of Jonas Ahlen and Thomas Gür as New Board Members

Bio-Works Technologies AB (Publ) Announces Executive Changes

Bio-Works Technologies AB (Publ) Announces Executive Changes

Bio-Works Technologies AB (publ) Announces Johan Sedihn Declines Re-Election as Member of Board

New major risk - Market cap size

New major risk - Share price stability

Independent Chairman of the Board recently bought kr510k worth of stock

Bio-Works Technologies AB (publ) to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings released: kr1.56 loss per share (vs kr1.28 loss in FY 2022)

Bio-Works Expands Product Range with Introduction of WorkBeads 40 Butyl SH

New major risk - Financial position

Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth

Independent Chairman of the Board recently bought kr275k worth of stock

Bio-Works Technologies AB (publ), Annual General Meeting, May 24, 2024

Independent Chairman of the Board recently bought kr908k worth of stock

New minor risk - Shareholder dilution

Bio-Works Technologies AB (Publ) Announces Appointment of Arne Hauge as Chief Financial Officer

Companies Like Bio-Works Technologies (STO:BIOWKS) Are In A Position To Invest In Growth

Price target decreased by 7.3% to kr25.50

Forecast to breakeven in 2025

Insufficient new directors

Bio-Works Implements Restructuring Program

We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bio-Works Technologies AB (publ) Wins EU Grant for Development of Environmentally-Friendly Purification of Biotherapeutics

We Think Bio-Works Technologies (STO:BIOWKS) Can Afford To Drive Business Growth

First half 2022 earnings released: kr0.66 loss per share (vs kr0.29 profit in 1H 2021)

Bio-Works Technologies AB (Publ) Launches GoBio, New Product Line Saves Time in Biotherapeutic Production

We Think Bio-Works Technologies (STO:BIOWKS) Can Easily Afford To Drive Business Growth

Independent Chairman of the Board recently bought kr358k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to kr29.50

Price target increased to kr25.50

Bio-Works Technologies (STO:BIOWKS) Is In A Strong Position To Grow Its Business

Is Bio-Works Technologies (STO:BIOWKS) In A Good Position To Invest In Growth?

Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Have Been Selling

Bio-Works Signs Licensing Agreement with Amicogen Inc to Establish Local Manufacturing of Agarose Resins in South Korea

New 90-day high: kr11.00

New 90-day high: kr9.54

New 90-day high: kr9.02

How Much Are Bio-Works Technologies AB (publ) (STO:BIOWKS) Insiders Taking Off The Table?

New 90-day low: kr7.94

Earnings released

New 90-day high - kr10.30

New 90-day high - kr8.44

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd